Shanghai Sanyou Medical Co Ltd
Shanghai Sanyou Medical Co., Ltd. researches, develops, manufactures, and sells orthopedics implants in China. The company offers spinal and trauma implants under Tytus and Sanyou brand. Its spinal products comprise anterior cervical plate, anterior thoracolumbar, posterior cervical, posterior thoracolumbar, and minimally invasive products; and trauma implants, including shoulder and elbow system… Read more
Shanghai Sanyou Medical Co Ltd (688085) - Net Assets
Latest net assets as of September 2025: CN¥2.10 Billion CNY
Based on the latest financial reports, Shanghai Sanyou Medical Co Ltd (688085) has net assets worth CN¥2.10 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.34 Billion) and total liabilities (CN¥247.79 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.10 Billion |
| % of Total Assets | 89.43% |
| Annual Growth Rate | 37.73% |
| 5-Year Change | 33.52% |
| 10-Year Change | N/A |
| Growth Volatility | 79.08 |
Shanghai Sanyou Medical Co Ltd - Net Assets Trend (2016–2024)
This chart illustrates how Shanghai Sanyou Medical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Shanghai Sanyou Medical Co Ltd (2016–2024)
The table below shows the annual net assets of Shanghai Sanyou Medical Co Ltd from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.05 Billion | +0.30% |
| 2023-12-31 | CN¥2.04 Billion | +6.78% |
| 2022-12-31 | CN¥1.91 Billion | +10.18% |
| 2021-12-31 | CN¥1.74 Billion | +13.15% |
| 2020-12-31 | CN¥1.53 Billion | +250.48% |
| 2019-12-31 | CN¥437.81 Million | +28.67% |
| 2018-12-31 | CN¥340.24 Million | +17.71% |
| 2017-12-31 | CN¥289.06 Million | +82.73% |
| 2016-12-31 | CN¥158.19 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shanghai Sanyou Medical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 26470.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥572.18 Million | 29.93% |
| Common Stock | CN¥248.45 Million | 13.00% |
| Other Comprehensive Income | CN¥80.60 Million | 4.22% |
| Other Components | CN¥1.01 Billion | 52.86% |
| Total Equity | CN¥1.91 Billion | 100.00% |
Shanghai Sanyou Medical Co Ltd Competitors by Market Cap
The table below lists competitors of Shanghai Sanyou Medical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AMC Entertainment Holdings Inc
NYSE:AMC
|
$567.81 Million |
|
Grocery Outlet Holding Corp
NASDAQ:GO
|
$567.87 Million |
|
Transcoal Pacific Tbk PT
JK:TCPI
|
$567.95 Million |
|
Festi hf
IC:FESTI
|
$568.02 Million |
|
Ribo Fashion Group Co Ltd
SHG:603196
|
$567.40 Million |
|
Lonking Holdings Limited
F:C9IB
|
$567.18 Million |
|
Etablissements Maurel et Prom SA
PA:MAU
|
$566.93 Million |
|
Henan Tong-Da Cable Co Ltd
SHE:002560
|
$566.83 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shanghai Sanyou Medical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,916,191,204 to 1,911,797,444, a change of -4,393,760 (-0.2%).
- Net income of 11,468,618 contributed positively to equity growth.
- Dividend payments of 22,650,683 reduced retained earnings.
- Other comprehensive income increased equity by 80,494,620.
- Other factors decreased equity by 73,706,315.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥11.47 Million | +0.6% |
| Dividends Paid | CN¥22.65 Million | -1.18% |
| Other Comprehensive Income | CN¥80.49 Million | +4.21% |
| Other Changes | CN¥-73.71 Million | -3.86% |
| Total Change | CN¥- | -0.23% |
Book Value vs Market Value Analysis
This analysis compares Shanghai Sanyou Medical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.91x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 29.43x to 2.91x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | CN¥0.70 | CN¥20.49 | x |
| 2017-12-31 | CN¥1.53 | CN¥20.49 | x |
| 2018-12-31 | CN¥1.51 | CN¥20.49 | x |
| 2019-12-31 | CN¥1.97 | CN¥20.49 | x |
| 2020-12-31 | CN¥5.62 | CN¥20.49 | x |
| 2021-12-31 | CN¥5.69 | CN¥20.49 | x |
| 2022-12-31 | CN¥6.19 | CN¥20.49 | x |
| 2023-12-31 | CN¥6.35 | CN¥20.49 | x |
| 2024-12-31 | CN¥7.05 | CN¥20.49 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shanghai Sanyou Medical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.60%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.53%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 1.21x
- Recent ROE (0.60%) is below the historical average (8.79%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 1.98% | 4.16% | 0.42x | 1.12x | CN¥-12.69 Million |
| 2017 | 1.80% | 3.72% | 0.42x | 1.16x | CN¥-23.71 Million |
| 2018 | 18.25% | 27.95% | 0.57x | 1.14x | CN¥28.09 Million |
| 2019 | 22.34% | 27.61% | 0.64x | 1.26x | CN¥54.04 Million |
| 2020 | 7.73% | 30.37% | 0.23x | 1.09x | CN¥-34.88 Million |
| 2021 | 11.05% | 31.41% | 0.30x | 1.18x | CN¥17.78 Million |
| 2022 | 10.37% | 29.39% | 0.30x | 1.19x | CN¥6.84 Million |
| 2023 | 4.99% | 21.04% | 0.20x | 1.18x | CN¥-96.04 Million |
| 2024 | 0.60% | 2.53% | 0.20x | 1.21x | CN¥-179.71 Million |
Industry Comparison
This section compares Shanghai Sanyou Medical Co Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,121,810,098
- Average return on equity (ROE) among peers: 128.89%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shanghai Sanyou Medical Co Ltd (688085) | CN¥2.10 Billion | 1.98% | 0.12x | $567.57 Million |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $1.03 Billion | 22.10% | 0.17x | $320.58 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $6.16 Billion | 12.22% | 0.29x | $2.80 Billion |
| Double Medical Technology Inc (002901) | $3.11 Billion | 2.98% | 0.27x | $405.66 Million |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $21.45K | 1180.66% | 90.26x | $283.55 Million |
| Lepu Medical Tech Beijing (300003) | $7.03 Billion | 12.79% | 0.82x | $2.80 Billion |
| INKON Life Technology Co Ltd (300143) | $74.89 Million | 13.27% | 0.87x | $630.90 Million |
| Edan Instruments Inc (300206) | $152.19 Million | 30.16% | 0.31x | $509.86 Million |
| Guangdong Biolight Meditech Co Ltd (300246) | $1.29 Billion | -5.53% | 0.94x | $378.42 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $1.44 Billion | 2.82% | 0.20x | $269.46 Million |
| Sinocare Inc (300298) | $946.01 Million | 17.47% | 0.11x | $952.60 Million |